G-protein subunit α-14 is dysregulated in human placentas from systemic lupus erythematosus pregnancies

Keywords
systemic lupus erythematosus, pregnancy, placenta, G-protein

Abstract
Introduction
Systemic lupus erythematosus (SLE) is associated with placental dysfunctions during pregnancy, which may cause multiple adverse fetal and maternal outcomes. G-protein subunits α-11 (GNA11) and α-14 (GNA14) participate actively in angiogenesis via the modulation of endothelial function. This study aimed to determine whether GNA11 and GNA14 levels in placental tissues differed between SLE and normal term pregnancies.

Material and methods
Twenty-four individuals, including 14 patients with SLE and 10 normal pregnant women, were included in this study. The expression levels of GNA11 and GNA14 in the placentas were examined using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blotting analyses. The localization of GNA11 and GNA14 in placental tissues was evaluated using immunohistochemistry. The correlations between relative mRNA and protein expression levels of GNA11,14 and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores were also analyzed.

Results
RT-qPCR revealed that the mRNA levels of GNA14, but not GNA11, were significantly decreased by 50% (P = 0.01) in SLE vs. normal term placentas. Western blotting showed that the protein levels of GNA14, but not GNA11, were significantly increased by 3.52-fold (P = 0.02) in SLE vs. normal term placentas. Using immunohistochemistry, positive staining for GNA11 and GNA14 was present in trophoblasts and villous stromal cells of the placental tissues. The expression levels of GNA11 and GNA14 were not significantly correlated with the SLEDAI scores (r^2=0.02~0.24, P = 0.08~0.75).

Conclusions
The dysregulation of GNA14 in the placentas indicates a regulatory role during human SLE pregnancies.

Explanation letter
Re: Responses to Reviewers’ Comments on AMS-13512-2021-02
The authors are very grateful to the editors and reviewers for their careful and constructive review. In this revision, we have addressed all of these comments. The reviewer's comments are in italic.

Reviewer comments:
Review 1:
The number of study participants is low. The study method is not adequately explained. It is inappropriate to take placental samples from the choronic side. The possible effect of vaginal birth on the selected gene expression is unclear.

Dear reviewer,
Thank you very much for the valuable suggestions. We have included additional samples in this study. Twenty-four individuals, including 14 patients with SLE and ten normal pregnant women, were included. We re-analyzed the RT-qPCR and Western blotting results and updated the results in this revision. We also modified the method section and added updated details in this revision. As for sampling from the chorionic side, the tissues we sampled were placental villi from beneath the chorionic and basal plates. Chorionic plate, amnion, and decidual endometrial tissue were removed. We modified the description in the method section and used, "Placental villi were dissected from beneath the chorionic and basal plates (~1×1 cm)."

Yes, we agree that vaginal birth and C-section may have different impacts on gene expression. In this revision, we included 14 patients with SLE and 10 normal pregnant women. Eight patients in the SLE group and 6 in normal term underwent vaginal delivery, without significantly different distribution between the two groups (Vaginal delivery (%) from SLE = 57.1% vs. 60% from the normal term, P = 0.89).

We went through our RT-qPCR data and compared the expression levels of GNA11/GNA14 of vaginal birth and C-section in the normal term group and the SLE group (n = 4, 4 from vaginal birth 4 from C-section). RT-qPCR analysis showed that no significance was detected in mRNA expression levels of vaginal birth and C-section for both GNA11 and GNA14 (Figure S1 in this revision). However, further research involving more patients number is required to confirm this finding. We updated this information in the Discussion section.

Thank you again for your professional and valuable comments.

**Respond to reviewer.docx**
G-protein subunit α-14 is dysregulated in human placentas from systemic lupus erythematosus pregnancies

Abstract

Introduction: Systemic lupus erythematosus (SLE) is associated with placental dysfunctions during pregnancy, which may cause multiple adverse fetal and maternal outcomes. G-protein subunits α-11 (GNA11) and -14 (GNA14) participate actively in angiogenesis via the modulation of endothelial function. This study aimed to determine whether GNA11 and GNA14 levels in placental tissues differed between SLE and normal term pregnancies.

Materials and methods: Twenty-four individuals, including 14 patients with SLE and 10 normal pregnant women, were included in this study. The expression levels of GNA11 and GNA14 in the placentas were examined using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blotting analyses. The localization of GNA11 and GNA14 in placental tissues was evaluated using immunohistochemistry. The correlations between relative mRNA and protein expression levels of GNA11,14 and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores were also analyzed.

Results: RT-qPCR revealed that the mRNA levels of GNA14, but not GNA11, were significantly decreased by 50% ($P = 0.01$) in SLE vs. normal term placentas. Western blotting showed that the protein levels of GNA14, but not GNA11, were significantly increased by 3.52-fold ($P = 0.02$) in SLE vs. normal term placentas. Using immunohistochemistry, positive staining for GNA11 and GNA14 was present in trophoblasts and villous stromal cells of the placental tissues. The expression levels of GNA11 and GNA14 were not significantly correlated with the SLEDAI scores ($r^2=0.02~0.24$, $P = 0.08~0.75$).
Conclusions: The dysregulation of GNA14 in the placentas indicates a regulatory role during human SLE pregnancies.

Keywords: Systemic lupus erythematosus, G-protein, placenta, pregnancy.
Introduction

Systemic lupus erythematosus (SLE) pregnancies are associated with several placental changes, including decreased placental weight, intraplacental hematoma, chronic villitis, ischemic hypoxic change, and placental infarction [1], which may result in adverse fetal outcomes, including preterm birth, stillbirth, spontaneous abortion, fetal growth restriction, and neonatal lupus [2, 3]. Additionally, maternal complications during SLE pregnancies include hypertension, preeclampsia, eclampsia, and lupus flare [2, 3].

G protein α subunit (GNA)11 and GNA14, members of Gaq/11 subfamily of G protein α subunit, have been shown to localize in different cell types of multiple human tissues, including endothelial and smooth muscle cells from lung tissues, endothelial and trophoblast cells from placentas, and tumor tissues [4-6]. Experimental data have demonstrated the essential roles of GNA11 and GNA14 in fibroblast growth factor 2 (FGF2)- and vascular endothelial growth factor (VEGF)- mediated fetoplacental endothelial cell functions and angiogenesis [7-9].

In this study, we aim to investigate the expression of GNA11 and GNA14 in human placental tissues obtained from normal term and SLE pregnancies. The correlations between expression levels of GNA11,14 and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores were also analyzed.

Materials and methods

Collection of placental tissues

The study was conducted in accordance with the 1964 Helsinki Declaration. Placental tissues from normal term (n = 10) pregnancies were collected in cc Hospital dd University. Tissue collection was approved by the Ethical Committee of cc Hospital dd University (Ethical approval number: KS2013). Placental tissues from SLE (n = 14) pregnancies were collected in aa Hospital,
Tissue collection was approved by the Institutional Review Board of a hospital, bb University (Ethical approval number: KYLL-2018-216). The American College of Rheumatology classification criteria was used to diagnose SLE [10]. The SLE disease activity index (SLEDAI) [11] was used to assess the disease activity of SLE patients. Informed consent was obtained from all participants. Smokers and participants with diabetes mellitus or cancer were excluded. Patient characteristics are described in Table I.

Placental tissues were obtained within 30 min after vaginal delivery or cesarean section delivery. Placental villi were dissected from beneath the chorionic and basal plates (~1×1 cm). After removal of the chorionic plate and amnion, chorionic tissues were snap-frozen in liquid nitrogen and stored at -80 °C. Additional tissues were fixed in 4% paraformaldehyde solution in PBS at 4°C overnight and embedded in paraffin before being sectioned for immunohistochemistry.

**RT-qPCR**

Total RNA was extracted using the RNeasy kit (Qiagen, cat#: 74004). RNA concentration was measured using a Nanodrop One spectrophotometer (Thermo Fisher Scientific). RNAs were transcribed into complementary DNA using the HiScript II Q RT SuperMix for qPCR (Vazyme Biotech, cat#: R222-01). RT-qPCR (n = 8/group) reactions were carried out using NuHi Robustic SYBR Green Mix (Nuhigh Biotechnologies, cat#: NH9211) on an ABI 7900 Sequence Detection System. The primer sequences are listed in Table II. The PCR protocol was: 95°C for 10 min, 40 cycles of 95°C for 15 s, and 60°C for 60 s. The melting curve analysis was used to confirm the amplification specificity. Data were normalized to GAPDH [12, 13]. The relative expression levels of GNA11 and GNA14 were analyzed using the $2^{-\Delta\Delta CT}$ method [14, 15].

**Western blotting**
Western blotting was performed as described [16, 17]. Placental tissues were homogenized on ice and lysed in lysis buffer (Cell Signaling, cat#: 9803) by sonication. Supernatants were obtained after centrifugation at 4°C for 20 min (12,000 g). Protein samples (100 μg) were added to the loading buffer and heated at 95 °C for 5 min to denature. Protein samples (n = 10 for normal term group and 14 for SLE group) were separated on 10% SDS-PAGE gel and transferred to polyvinylidene difluoride membranes. Tris-buffered saline was used to prepare solutions including blocking buffer and antibody solutions. After blocking with 5% skim milk in TBS buffer for 1h, the membranes were probed with GNA11 (1:1000, Abgent, cat#: AP19441a) or GNA14 antibody (1:500, Abnova, cat#: H00009630-M06A) 4°C overnight, followed by reprobing with GAPDH (1:10,000; Abnova, cat#: H00002597-M01) as controls. Secondary antibodies were incubated with membranes at room temperature for 1 h. Protein immunoreactivity was visualized with ECL2 or ECL reagent (Thermo Fisher Scientific, cat#: 80196; 32106). Densitometry data obtained by the NIH Image-J imaging analysis software (Bethesda, Maryland, USA) was used to quantify the protein expression levels of GNA11 and GNA14.

**Immunohistochemistry**

Immunohistochemistry was performed as previously described [18, 19]. Paraffin-embedded placental tissues (n = 4/group) were sliced into 4μm thickness sections. Antigen retrieval was performed in citrate acid solution (10mM citrate acid, PH 6.5) and boiled for 10 min. Endogenous peroxidase was quenched using 3% hydrogen peroxide at room temperature for 10 min. After being blocked with blocking serum at room temperature for 30 min, tissue sections were probed with primary antibodies diluted in 10mM PBS/0.3% Triton-X100 against GNA11 (4 μg/ml, Abgent, cat#: AP19441a) or GNA14 (4 μg/ml, Abnova, cat#: H00009630-M06A) at 4°C.
overnight and then incubated with a biotinylated universal secondary antibody (Vector Laboratories, BP-1400-50) at room temperature for 30 min. The staining was visualized with AEC Substrate Kit (Vector Laboratories, cat#: SK-4200) at room temperature for up to 20 min. Brownish-yellow staining was considered as giving a positive signal. Finally, tissue sections were re-stained with hematoxylin for 5 min.

**Correlation analysis of GNA11, 14 levels and SLEDAI scores**

According to RT-qPCR and Western blotting data, relative expression levels of GNA11 and GNA14 (fold of normal term) were used to analyze correlation with SLEDAI scores.

**Statistical analysis**

Data were expressed as medians ± standard deviation or medians with ranges. Data were analyzed using Mann-Whitney Rank Sum Test or student’s t-test when applicable. The correlation analysis was performed using Pearson’s correlation coefficient. P-values < 0.05 were considered statistically significant. Sample size calculation (power analysis) was analyzed according to the study of Rosner B [20]. The statistics results in the current study are reliable based on the sample size that we used. SigmaPlot (13.0) for Windows was used for statistical analyses.

**Results**

All SLE patients received maintenance corticosteroids (prednisone ≤ 15 mg daily) and hydroxychloroquine (≤ 400mg daily) during pregnancy. The SLEDAI scores prior to delivery ranged from 0-6. None of the newborns developed neonatal lupus. Maternal ages and body mass index (BMI) were similar between normal term and SLE. Gestation ages for SLE pregnancies (38.4 ± 1.3 weeks) were lower ($P = 0.02$) than in normal term pregnancies (39.1 ± 0.6 weeks). Fetal weights for SLE pregnancies (2950.0 ± 442.1 g) were lower ($P = 0.01$) than in normal term
pregnancies (3402.5 ± 262.0 g). Six patients in normal term and eight in SLE group, underwent vaginal delivery, without significantly different distribution between two groups.

RT-qPCR was conducted to examine GNA11 and GNA14 mRNA relative expression levels in SLE and normal term placentas. The mRNA levels of GNA14, but not GNA11, were significantly decreased by 50% ($P = 0.01$) in SLE vs. normal term placentas.

Western blotting analysis showed that GNA11 and GNA14 proteins were detected at ~42 kD (Figure 1). The protein levels of GNA14, but not GNA11, were significantly increased by 3.52-fold ($P = 0.02$) in SLE vs. normal term placentas when normalized to GAPDH (Figure 1).

Immunohistochemistry was conducted to examine the localization of GNA11 and GNA14 in SLE and normal term placentas. GNA11 and GNA14 were localized in trophoblasts and villous stromal cells in SLE and normal term placentas (Figure 2).

We further analyzed the correlation between expression levels of GNA11, 14, and SLEDAI scores of SLE patients. The relative mRNA and protein expression levels of GNA11 and GNA14 were not significantly correlated with the SLEDAI scores ($r^2 = 0.02$-$0.24$, $P = 0.08$-$0.75$; Figure 3).

**Discussion**

Our study demonstrates the localization and expression levels of GNA11 and GNA14 in human placentas from normal term and SLE pregnancies. We have observed that GNA11 and GNA14 are localized in different cell types in human placental tissues, including trophoblasts and villous stromal cells. Our findings agree with a previous study concerning umbilical cord and placental tissues from preeclampsia patients that GNA11 and GNA14 are present in endothelial cells, trophoblasts, and villous stromal cells [5]. More importantly, we have demonstrated that GNA14, and not GNA11, is downregulated in SLE vs. normal term at mRNA levels in placentas;
however, GNA14, and not GNA11, is upregulated in SLE vs. normal term at protein levels. These data suggest that GNA11 and GNA14 may be associated with placental cell functions, and GNA14 may play a unique role in regulating placental functions during SLE pregnancies.

Downregulation of GNA14 at mRNA levels and upregulation at protein levels indicate a discordant expression between mRNA and protein levels from SLE vs. normal term placentas. Studies investigating the correlations between mRNA and protein abundance in human tissues are controversial [21-23]. A study involving 23 human cell lines showed that correlations were only detected in one-thirds of the mRNA and corresponding proteins [24]. In this study, two different delivery methods, vaginal birth and C-section, were performed, which may have different impacts on gene expression. However, no significantly different distribution between two groups (Vaginal delivery [%] from SLE group = 57.1% vs. 60% from the normal term group, $P = 0.89$). Subgroup RT-qPCR analysis showed that no significance was detected in mRNA expression levels of vaginal birth and C-section for both GNA11 and GNA14 in both groups (Figure S1, $P = 0.28$-$0.44$). Further studies involving more patients number are required to confirm this finding. Besides, several reasons may contribute to the absence of a strong correlation between mRNA and protein levels. First, post-transcriptional and/or post-translational mechanisms are complicated and varied among different genes [21]; second, proteins have different half-lives [25]; third, there are error and noise in mRNA and protein experiments [21]; additionally, alternative methods of examination may result in different data with varied correlations. The above reasons may contribute to the discordant expression levels of GNA14 between mRNA and protein levels from SLE placentas in this study.

GNA11 and GNA14 have been demonstrated to play essential roles in fetoplacental endothelial cell functions and angiogenesis [7-9]. The current finding that GNA14, but not
GNA11, is dysregulated in SLE placentas implies that GNA14 may be a unique mediator in placentas from SLE pregnancies, in which dysfunction of angiogenesis may be involved. Higher levels of angiogenic activity have been reported in serum samples from patients with SLE, which is associated with SLE disease activity [26]. Our bioinformatics data concerning differential expressed genes of placentas between SLE and normal control pregnancy also showed that angiogenesis (Gene Ontology term: GO:0001525) was enriched (data not shown), suggesting that dysfunction of angiogenesis may be associated with placental development during SLE pregnancies. The dysregulation of GNA14 in the placentas suggests its regulatory role in placental angiogenesis during SLE pregnancies, which may lead to dysfunction of the placentas [27]. However, the function of GNA14 in SLE placental cells remains unclear. Further functional studies are warranted to explore the potential mechanisms of GNA14 in the angiogenesis function of SLE placentas.

It remains elusive what causes the dysregulation of GNA14 in SLE placentas. In the current study, gestation ages and fetal weights from the SLE group were lower than the controls, which is in line with the evidence that SLE pregnancies are associated with adverse pregnancy outcomes, including preterm birth and fetal growth restriction [2, 3]. The aberrant expression of GNA14 in placentas may attribute to different gestation ages and fetal weights between SLE and normal term pregnancies. New reliable clinical biomarkers may provide novel therapies for SLE. The dysregulation of GNA14 in SLE placentas suggests that GNA14 might become a potential biomarker and therapeutic target for SLE. However, the correlation analysis in this study did not show statistical significance between SLEDAI scores and GNA14 expression levels in SLE placentas. A small case number may contribute to the above finding. Meanwhile, SLEDAI scores of SLE patients in this study ranged from 0-6, and the limited SLEDAI score range may limit the
correlation analysis. Further studies involving a larger patient number and wider SLEDAI score range are necessary to investigate the potential roles of GNA14 during SLE pregnancies.

To our knowledge, this is the first report investigating the mRNA and protein expression levels of GNA11 and GNA14 in placental tissues from SLE pregnancies. The current results suggest that GNA11 and GNA14 may participate in placental cellular functions. The dysregulation of GNA14 in the SLE placentas suggests that GNA14 may contribute to the dysfunction of placental cells during SLE pregnancies, and GNA14 might serve as a potential biomarker and therapeutic target for SLE. Meanwhile, there are several limitations to this study. First, we were limited by the small sample size. Second, low disease activity (SLEDAI scores from 0-6) of SLE patients included in this study restrained us from exploring the relationship between GNA11 and GNA14 levels with patients with higher SLEDAI scores. Further studies are necessary to define the potential roles of GNA11 and GNA14 during SLE pregnancies.

In conclusion, the current data provide evidence that GNA14 is dysregulated in human SLE placentas. The dysregulation of GNA14 in the placentas indicates a regulatory role during SLE pregnancies.
References


Legends of figures

Figure 1. GNA11 and GNA14 expression patterns in human placentas. (a, b) RT-qPCR and Western blotting analyses. (c) Representative Western blotting for the GNA and GNA14 protein levels (100 µg of each placental sample) in human placentas from systemic lupus erythematosus (SLE) and normal term pregnancies (n=10~14/group). *P < 0.05.

Figure 2. Immunolocalization of GNA11 and GNA14 in human placentas from systemic lupus erythematosus (SLE) and normal term pregnancies.*: lumen of blood vessels; arrows: syncytiotrophoblast; arrowheads: cytotrophoblast.

Figure 3. Correlation analyses between GNA11, 14 expression levels and SLEDAI scores. Relative expression levels of GNA11 and GNA14 were obtained using RT-qPCR and Western blotting analyses. Correlations between SLEDAI scores and expression levels of GNA11 and GNA14 (Fold of the normal term) were analyzed using Pearson's correlation coefficient.

Figure S1. GNA11 and GNA14 subgroup mRNA expression levels in human placentas.
Table I. Clinical and laboratory characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>SLE (n = 14)</th>
<th>Normal Term (n = 10)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (range)</td>
<td>29.0 (22-36)</td>
<td>30.5 (28-33)</td>
<td>0.40</td>
</tr>
<tr>
<td>BMI, median (range)</td>
<td>24.9 (22.4-32.3)</td>
<td>28.0 (21.8-32.7)</td>
<td>0.29</td>
</tr>
<tr>
<td>Vaginal delivery, n (%)</td>
<td>8 (57.1%)</td>
<td>6 (60%)</td>
<td>0.89</td>
</tr>
<tr>
<td>Gestation age (weeks), median (range)</td>
<td>38.4 (34.9-39.7)</td>
<td>39.1 (38.6-40.1)</td>
<td>0.02</td>
</tr>
<tr>
<td>Fetal weight (grams), median (range)</td>
<td>2950.0 (2150.0-3850.0)</td>
<td>3402.5 (2895.0-3730.0)</td>
<td>0.01</td>
</tr>
<tr>
<td>Disease duration (months), median (range)</td>
<td>46.5 (10-167)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLEDAI score, median (range)</td>
<td>2 (0-6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANA &gt; 1:320, yes/no (n)</td>
<td>14/0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-dsDNA, yes/no (n)</td>
<td>2/12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-phospholipid, yes/no (n)</td>
<td>4/10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preeclampsia, yes/no (n)</td>
<td>0/14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proteinuria, yes/no (n)</td>
<td>3/11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypocomplementemia, yes/no (n)</td>
<td>7/7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steroids, yes/no (n)</td>
<td>14/0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunosuppressive drugs, yes/no (n)</td>
<td>0/14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin, yes/no (n)</td>
<td>4/10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SLE, systemic lupus erythematosus; BMI, body mass index; SLEDAI, systemic lupus erythematosus disease activity index; ANA, antinuclear antibody
<table>
<thead>
<tr>
<th>Gene ID</th>
<th>Gene Name</th>
<th>Forward (5’-3’)</th>
<th>Reverse (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENSG00000111640</td>
<td>GAPDH</td>
<td>TGACTTCAACAGCGACACCCA</td>
<td>CACCCTGTTGCTGTAGCCAAA</td>
</tr>
<tr>
<td>ENSG00000088256</td>
<td>GNA11</td>
<td>GCATGTGGGGTGTGTGTTT</td>
<td>ATGGTCGGAGAAGGTGGTC</td>
</tr>
<tr>
<td>ENSG00000156049</td>
<td>GNA14</td>
<td>GCCCACTCCTCCCTATAA</td>
<td>GGCTGGCTCTGGTGATGT</td>
</tr>
</tbody>
</table>